Case 75

Published on 13/02/2015 by admin

Filed under Cardiovascular

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1088 times

CASE 75

image
image
image
image

ANSWERS

CASE 75

Cardiac Sarcoidosis

1A and E

2D

3A

4B

References

Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683–1690.

Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97(24):2078–2087.

Cross-Reference

Cardiac Imaging: The REQUISITES, ed 3, pp 89, 92.

Comment

Imaging

Short-axis and four-chamber images show patchy late gadolinium enhancement that does not follow a typical vascular distribution and spares the subendocardial layer (Figs. AC). T2-weighted black blood short-axis image shows no hyperintensity to indicate active inflammation (Fig. D). This patient had pulmonary sarcoidosis and was given a presumptive diagnosis of cardiac sarcoidosis based on the MRI findings.

Epidemiology

Myocardial involvement by sarcoidosis is uncommon, clinically affecting approximately 5% of all patients with the disease. Autopsy series show cardiac involvement in 27% of asymptomatic patients. The cardiovascular system is the third most commonly affected organ system. When the heart is involved, patients may be asymptomatic but are at greater risk for acute heart failure, arrhythmia, and sudden cardiac death. Sarcoidosis most commonly affects the myocardium; specifically, there is often sparing of the subendocardium with involvement of the basal septum, left ventricular free wall, and right ventricular free wall.